By Colin Kellaher
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.
Miami biopharmaceutical company Summit said it will provide ivonescimab for use in the proposed studies, slated to begin in the middle of the year, with New York drugmaker Pfizer being responsible for conducting the studies.
Summit has licensed the rights to ivonescimab in North and South America, Europe, the Middle East, Africa and Japan from Chinese biotech Akeso, which engineered the drug.
Summit last year reported data from a late-stage study that showed ivonescimab beat Merck's blockbuster cancer drug Keytruda in patients with a form of lung cancer.
Pfizer is developing several ADCs, which work like guided missiles by pairing antibodies with toxic agents to fight cancer.
Shares of Summit were recently up 7.3% at $23.73 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 24, 2025 06:44 ET (11:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.